Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Topics:
Thoracic Malignancies
•
Medical Oncology
•
NCI-CCC Tumor Board Question
•
Non-small cell lung cancer
•
Vanderbilt
•
NCI-CCC Thoracic Tumor Board Question
Due to the high incidence of hyperlipidemia secondary to lorlatinib, do you provide empiric statin therapy to all patients without known contraindications upon initiation of lorlatinib?
Related Questions
Do you offer local consolidative therapy for patients with polymetastatic driver mutation-positive NSCLC who respond well to targeted therapy?
What is your approach to adjuvant therapy for an R0, ALK+ resected lung adenocarcinoma with N2 disease?
Do you prefer cisplatin or carboplatin in combination with nivolumab per CheckMate 816 for patients with resectable NSCLC?
Would you add ALK-targeted therapy for patients with EGFR L858R-mutant lung adenocarcinoma who progress on targeted therapy and develop a concomitant STRN-ALK fusion?
What is your preferred management for diffuse idiopathic pulmonary neuroendocrine cell hyperplasia (DIPNECH)?
For patients with metastatic thymic carcinoma, is there a role for local treatment options such as SBRT for oligoprogressive or oligopersistent disease after systemic therapy?
How would you treat a potentially resectable stage III lung adenocarcinoma with an EGFR mutation?
Which targeted therapies should we be more cautious of giving after recent immunotherapy in NSCLC?
What is your preferred first line approach to patients with Stage IV non-squamous NSCLC with good performance status, no driver mutations, PD-L1 low-positive, and CKD IIIB or worse, CrCl < 45 mL/min?
For patients who undergo sublobar resection for early stage NSCLC with LN sampling found to have unexpected N2 positive disease, would you consider neoadjuvant chemoimmunotherapy followed by completion lobectomy or proceed directly to adjuvant therapy?